Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes

Cilt: 41 Sayı: 2 30 Haziran 2016
Kübra Kurt , Lale Dönbak , Ahmet Kayraldız
PDF İndir
EN TR

Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes

Abstract

Purpose: Antiretroviral drugs used in the treatment of HIV (Human Immünodeficiency Virus) iınfection, treat by preventing the proliferation of HIV in human body. People with HIV have to use this drugs for lifelong because of inability of the drugs to eradicate the viruses. In this study, we investigated the in vitro genotoxic activity of tenofovir disoproxil fumarate one of the antiretroviral drugs, in human peripheral lymphocytes. 
Material and Methods: The cells were treated with four different concentrations of tenofovir disoproxil fumarate for 24 and 48 hours. The levels of sister chromatid exchanges, chromosomal aberrations, and micronucleus in the cells were examined for the genotoxic activity of tenofovir disoproxil fumarate. Mitotic index, proliferation index, and nucleer division index of treated cells were also determined for the cytotoxic effect of tenofovir disoproxil fumarate. 
Results: There was no significant differences in the level of sister chromatid exchanges, chromosomal aberrations, and micronucleus in human lyphocytes treated with all concetrations of tenofovir disoproxil fumarate for all treatment period as compared to control group. Similarly, it was observed that treatment of tenofovir disoproxil fumarate did not affect the mitotic index, proliferation index, and nucleer division index values. 
Conclusion: As a result, in this study, it is demonstrated that tenofovir disoproxil fumarate did not have genotoxic or cytotoxic effect in the human peripheral lymphocytes.

Keywords

-

Kaynakça

  1. Serter D. Türkiye'de ve dünyada cinsel yolla bulaşan enfeksiyonlar ve HIV/AIDS. Türkiye Klinikleri Tıp Bilimleri Dergisi. 2006;2:1-5.
  2. Açıoğlu S, Ünal S. Cinsel Yolla Bulaşan Hastalıkların Epidemiyolojisi. Ankara, Bilim Tıp Yayınevi, 2001.
  3. Tümer A. AİDS nedir? Dünyada ve Türkiye’de HIV/AIDS. AIDS_web2014.pdf (Erişim tarihi Haziran 2015).
  4. Sulukan EE, Küçükoğlu K, Gül Hİ. AIDS ve tedavisinde kullanılan ilaçlar. Ankara Eczacılık Fakültesi Dergisi. 2009;38:47-78.
  5. Türker N, Örmen B. Antiretroviral tedavi. İnfeksiyon Dergisi. 2006;20:207-17.
  6. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society- USA Panel. JAMA. 2008;300:555-70.
  7. Karaosmanoğlu HK, Aydın ÖA, Özyiğit F, İnce ER, Korkusuz R, Nazlıcan Ö. Antiretroviral tedavi ile ilişkili yan etkiler: 260 HIV/AIDS olgusunun değerlendirilmesi. 2013;6:118-21. Tıp Dergisi.
  8. Calmy A, Hirschel B, Cooper DA, Carr A. A new era of antiretroviral drug toxicity. Antivir Ther. 2009;14:165-79.
  9. Brambilla G, Mattioli F, Robbiano L, Martelli A. Studies on genotoxicity and carcinogenicity of antibacterial, antiviral, antimalarial and antifungal drugs. Mutagenesis. 2012;27:387-413.
  10. Wutzler P, Thust R. Genetic risks of antiviral nucleoside analogues-a survey. Antiviral Res. 2001;49:55-74.

Kaynak Göster

MLA
Kurt, Kübra, vd. “Evaluation of genotoxic activity of tenofovir disoproxil fumarate in human peripheral lymphocytes”. Cukurova Medical Journal, c. 41, sy 2, Haziran 2016, ss. 229-35, doi:10.17826/cutf.199622.